Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of i (C. Difficile) toxin B associated conditions

A technology for Clostridium difficile toxins and toxins, which can be applied in the directions of antitoxins, medical preparations with non-active ingredients, and medical preparations containing active ingredients, and can solve problems such as interference

Inactive Publication Date: 2001-06-06
SYNSORB BIOTECH INC
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Disadvantages of this method include the length of time required to obtain results, and interference from non-toxigenic C. difficile strains (which do not produce toxins)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of i (C. Difficile) toxin B associated conditions
  • Treatment of i (C. Difficile) toxin B associated conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0150] Example 1 Determination of the conditions for the combination of toxin B and isomaltotriose SYNSORB

[0151]By incubating 20 mg of isomaltotriose SYNSORB (5-128) or Chromosorb sample with 1 mL of purified toxin B solution in a 1.5 mL microcentrifuge tube on a vertical cylinder rotor for 1, 2 and 4 hours at room temperature, Conditions required for toxin B binding were determined. Control tubes containing toxin B solution but without SYNSORB or Chromosorb were incubated simultaneously. The optimal amount of isomaltotriose SYNSORB required for maximal toxin B neutralization was determined by incubating immobilized isomaltotriose (10, 20 or 40 mg) with 1 ml of toxin B for 2 hours at room temperature. The amount of toxin activity in each sample was determined using CHO cells. After incubation, SYNSORB is pelleted to the bottom of the tube and the supernatant is carefully removed. Serial 5-fold dilutions of supernatants were prepared and assayed for cytotoxicity endpoints...

Embodiment 2

[0153] Screening for oligosaccharides that neutralize toxin B

[0154] In a 1.5 ml microcentrifuge tube, a solution containing purified toxin B (1 ml) was added to various SYNSORBs containing different oligosaccharide sequences listed in Table 1 and incubated on a vertical cylinder rotor at room temperature for 4 Hour. The amount of neutralization for each sample was determined by comparing the CHO cell cytotoxic endpoint titers of the samples with and without SYNSORB.

[0155] As shown in Table 1, with the exception of βGlc, all tested oligosaccharides effectively neutralized toxin B cell toxicity. Therefore, oligosaccharides αGlc(1-2)βGal, αGlc(1-4)βGlc (maltose), βGlc(1-4)βGlc (cellobiose), αGlc(1-6)αGlc(1-6)αGlc( Isomaltotriose), αGlc(1-6)αGlc (isomaltose), and βGlcNAc(1-4)βGlcNAc (chitobiose) bind toxin B.

Embodiment 3

[0157] Toxin A neutralization assay using isomaltose and isomaltotriose SYNSORB In a 0.5 mL microcentrifuge tube, a solution containing purified toxin A (1 mL) was added to isomaltose or isomaltotriose SYNSORB (10 or 20 mg), incubate for 1 hour at 4°C or room temperature on a vertical cylinder rotor. After incubation, SYNSORB is pelleted to the bottom of the tube and the supernatant is carefully removed. Serial two-fold dilutions of supernatants were prepared in Tris-buffered saline (TBS) and the hemagglutination endpoint determined as described above. The reduction in endpoints in the presence of either SYNSORB was determined as compared to a control in which no SYNSORB was added. We did not detect any binding of toxin A to isomaltose or isomaltotriose SYNSORB, suggesting that toxin A has binding specificity distinct from toxin B.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to prevention and / or treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with C. difficile infection, using oligosaccharide compositions which bind C. difficile toxin B, More specifically, the invention concerns neutralization of C. difficile toxin B associated with such conditions.

Description

Background of the invention [0001] The present invention relates to the treatment of antibiotic-associated diarrhea, including Clostridium difficile (Clostridium difficile)-associated diarrhea (CDAD) and pseudomembranous colitis (PMC) and other diseases associated with Clostridium difficile infection. More particularly, the invention relates to the neutralization of C. difficile toxin B, a cytotoxin associated with CDAD, PMC and other diseases caused by C. difficile. references [0002] The following references are cited in this application by numbering within parentheses in the relevant part of the application. [0003] 1. Bartlett, J.G. et al., "Antibiotic-Associated Pseudomembranous Colitis Caused by Toxin-Producing Clostridium sp.," New England Journal of Medicine (N. Engl. J. Med), 298:531-534 (1978). [0004] 2. Lyerly, D.M., "Epidemiology of Clostridium difficile disease," Clin. Microbiol. News 15: 49-53 (1993). [0005] 3. Cozart, H.C., et al., "Clostridium diffi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/70A61K31/7016A61K31/702A61K31/715A61K47/48A61P1/04A61P1/12A61P39/02
CPCA61K47/48861A61K31/715A61K47/48092Y10S514/867A61K47/549A61K47/6923A61P1/04A61P1/12A61P29/00A61P31/00A61P39/02A61P43/00
Inventor G·D·阿姆斯特朗L·D·希尔兹
Owner SYNSORB BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com